Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (289 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: heartqtcintervalsyndromelimit
  Phrases that lowered it: hcvhepatitisvisitinteractionevaluate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Sponsor's past trials: 5 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients NCT01650649 · started 2012 · scored riskier than 15% of active trials completed
• Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients NCT01558934 · started 2012 · scored riskier than 8% of active trials completed
• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers NCT01999114 · started 2012 · scored riskier than 7% of active trials completed
• The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects NCT02243241 · started 2012 · scored riskier than 5% of active trials completed
• Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal NCT01863186 · started 2013 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.